Life Science Intermediates Market Consolidation: Who will not survive?
- Will the industry consolidate, decentralize, or undergo a bimodal transformation?
- How will the current trends affect the major market segments?
- Which companies will enter the market and which will not survive?
- Internally developed and acquired technologies, and related capabilities.
- Proprietary technologies and patent litigations.
Contains 35 pages
1. BASF
2. CAMBREX
3. CLARIANT
4. DOWPHARMA
5. DSM
6. EVONIK
7. LANXESS
8. LONZA
9. NOVASEP
10. RHODIA
FOR EACH COMPANY, THE REPORT PRESENTS:
Internally developed and acquired technologies, and related capabilities.
Proprietary technologies and patent litigations.
2. CAMBREX
3. CLARIANT
4. DOWPHARMA
5. DSM
6. EVONIK
7. LANXESS
8. LONZA
9. NOVASEP
10. RHODIA
FOR EACH COMPANY, THE REPORT PRESENTS:
Internally developed and acquired technologies, and related capabilities.
Proprietary technologies and patent litigations.